Merck And Hanmi Partner In First Of A Kind Deal In South Korea
This article was originally published in PharmAsia News
Executive Summary
SEOUL - MSD Korea, Merck's South Korea branch, will sell a combination antihypertensive in South Korea in partnership with Hanmi Pharmaceutical, marking the first case in South Korea of a multinational company co-marketing a drug developed in part by a South Korean drug manufacturer
You may also be interested in...
Hanmi Sees Double Again: Files For Combination Of Sanofi’s Aprovel And Pfizer’s Lipitor
A deal with Sanofi draws upon a 2009 co-marketing deal by Hanmi with Merck & Co. Inc. to pave the way.
Merck And Korea's Hanmi Build On Cozaar Deal From One Country To More Than 30, And More Could Be On The Way
SEOUL - Merck & Co. Inc.'s emphasis on lifecycle management for its Cozaar brand is good news for Hanmi Pharmaceutical, as Merck recently expanded a marketing rights deal for Hanmi's ARB/CCB combination that pairs amlodipine with Merck's losartan. A deal that started in 2009 for the Korean market now stands at 30 markets and signs point to an even broader deal in the future
Merck And Korea's Hanmi Build On Cozaar Deal From One Country To More Than 30, And More Could Be On The Way
SEOUL - Merck & Co. Inc.'s emphasis on lifecycle management for its Cozaar brand is good news for Hanmi Pharmaceutical, as Merck recently expanded a marketing rights deal for Hanmi's ARB/CCB combination that pairs amlodipine with Merck's losartan. A deal that started in 2009 for the Korean market now stands at 30 markets and signs point to an even broader deal in the future